Keros Therapeutics Is Maintained at Buy by Truist Securities

Dow JonesDec 23 07:51 ET · Ratings

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43

Moomoo NewsDec 23 07:33 ET · Ratings

Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating

MT NewswiresDec 23 06:52 ET · Ratings

Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential

TipRanksDec 23 06:45 ET · Ratings

Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63

Moomoo NewsDec 16 08:31 ET · Ratings

Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63

BenzingaDec 16 08:02 ET · Ratings